Ironwood Pharmaceuticals Inc - Class A

-$0.11 (-1.8%)
Closing price May 24, 2024

IRWD Chart and Intraday Price

IRWD Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,418.94M USD
Shares Outstanding 156,529,000
Ironwood Pharmaceuticals Inc specializes in creating gastrointestinal (GI) treatments, offering relief for conditions like irritable bowel syndrome and chronic constipation through its flagship product, LINZESS. Beyond its core offerings, the company is exploring new therapies for visceral pain and rare diseases, including short bowel syndrome and primary biliary cholangitis. With strategic partnerships enhancing its reach, Ironwood stands out in the healthcare sector for its innovative approach to GI disorders and commitment to improving patient quality of life.

IRWD Articles

Tuesday's top analyst upgrades and downgrades included Broadcom, Ciena, Deere, FedEx, IMAX, Ironwood Pharmaceuticals, Lululemon Athletica, LyondellBasell Industries, Nvidia and Starbucks.
The top analyst upgrades, downgrades and initiations seen for Monday included Allscripts Healthcare Solutions, AmeriGas Partners, CVS Health, IMAX, Kraft Heinz, Marathon Oil, Microsoft and Pfizer.
The top analyst upgrades, downgrades and initiations seen on Wednesday included AIG, Freeport-McMoRan, Frontier Communications, Noble Energy, Occidental Petroleum, Spark Therapeutics and Target.
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
The top analyst upgrades, downgrades and other research calls from Monday include AECOM, Ciena, Evoqua Water Tech, Funko, GlaxoSmithKline and Square.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and Drug Administration (FDA) approval for its gout treatment...
After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the industry, biotech stocks are showing some signs of life.
The top analyst upgrades, downgrades and other research calls from Wednesday include Anadarko, Apple, Charter Communications, FireEye, First Solar and Frontier Communications.
Wednesday's top analyst upgrades, downgrades and initiations include Alphabet, Apple, Duke Energy, Kellogg, NVIDIA and Wells Fargo.
The top analyst upgrades, downgrades and initiations seen on Monday, March 21, include AK Steel, Intel, Symantec, Tesla, US Steel and Valeant Pharmaceuticals.
These are the top analyst upgrades and downgrades covered by 24/7 Wall St. on Thursday, September 4, 2014.
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at Credit Suisse.
Source: ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in...
Source: Jon OggOne of the biggest complaints for years about Wall St. research was that no firm ever said when to sell. Back in the halcyon days of the late 1980s, and through the 1990s, many stock...